Abstract
Proteins are posed as the natural counterpart of the synthetic polymers for the development of drug delivery systems and few of them, have been regarded safe for drug delivery purposes by the United States Food and Drug Administration (FDA). Serum albumin is the most abundant protein in human blood. Interest in the exploration of pharmaceutical applications of albumin-based drug delivery carriers, especially for the delivery of chemotherapeutic agents, has increased in recent years. Albumin has several advantages over synthetic polymers, as it is biocompatible, biodegradable, has low cytotoxicity and has an excellent binding capacity with various drugs. Micro- and nano-carriers not only protect active pharmaceutical ingredients against degradation, but also offer a prolonged release of drugs in a controlled fashion. Since existing tumour chemotherapeutic agents neither target tumour cells, nor are they specific to tumour cells, a slow release of drugs from carriers would be beneficial in targeting carcinogenic cells intracellularly. This article aims at providing an overview of pharmaceutical applications of albumin as a drug delivery carrier in tumour chemotherapy.
Keywords: Albumin, cancer, chemotherapy, drug delivery, microspheres, nanoparticles.
Current Cancer Drug Targets
Title:Bioactive Albumin-Based Carriers for Tumour Chemotherapy
Volume: 14 Issue: 8
Author(s): Yasser Shahzad, Ikram U. Khan, Talib Hussain, Alamgeer, Christophe A. Serra, Syed A.A. Rizvi, Minja Gerber and Jeanetta du Pless
Affiliation:
Keywords: Albumin, cancer, chemotherapy, drug delivery, microspheres, nanoparticles.
Abstract: Proteins are posed as the natural counterpart of the synthetic polymers for the development of drug delivery systems and few of them, have been regarded safe for drug delivery purposes by the United States Food and Drug Administration (FDA). Serum albumin is the most abundant protein in human blood. Interest in the exploration of pharmaceutical applications of albumin-based drug delivery carriers, especially for the delivery of chemotherapeutic agents, has increased in recent years. Albumin has several advantages over synthetic polymers, as it is biocompatible, biodegradable, has low cytotoxicity and has an excellent binding capacity with various drugs. Micro- and nano-carriers not only protect active pharmaceutical ingredients against degradation, but also offer a prolonged release of drugs in a controlled fashion. Since existing tumour chemotherapeutic agents neither target tumour cells, nor are they specific to tumour cells, a slow release of drugs from carriers would be beneficial in targeting carcinogenic cells intracellularly. This article aims at providing an overview of pharmaceutical applications of albumin as a drug delivery carrier in tumour chemotherapy.
Export Options
About this article
Cite this article as:
Shahzad Yasser, U. Khan Ikram, Hussain Talib, Alamgeer , A. Serra Christophe, A.A. Rizvi Syed, Gerber Minja and du Pless Jeanetta, Bioactive Albumin-Based Carriers for Tumour Chemotherapy, Current Cancer Drug Targets 2014; 14 (8) . https://dx.doi.org/10.2174/1568009614666141028100640
DOI https://dx.doi.org/10.2174/1568009614666141028100640 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antibodies and their Multivalent Constructs for Cancer Therapy
Protein & Peptide Letters Pharmacological Inhibition of Exosome Machinery: An Emerging Prospect in Cancer Therapeutics
Current Cancer Drug Targets A Review of Ewing Sarcoma Treatment: Is it Still a Subject of Debate?
Reviews on Recent Clinical Trials Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Infectious Disorders - Drug Targets L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management
Current Medicinal Chemistry Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Mesenchymal Stem Cells: Use in Cartilage Repair
Current Rheumatology Reviews Targeting the LKB1 Tumor Suppressor
Current Drug Targets Curcumin in Combined Cancer Therapy
Current Pharmaceutical Design Risk Assessment of the Use of Autonomous Parvovirus-Based Vectors
Current Gene Therapy Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets A Brief Introduction to Porphyrin Compounds used in Tumor Imaging and Therapies
Mini-Reviews in Medicinal Chemistry Antiproliferative Effects of Molecular Iodine in Cancers
Current Chemical Biology Advances of Paclitaxel Formulations Based on Nanosystem Delivery Technology
Mini-Reviews in Medicinal Chemistry Current Advances and Therapeutic Potential of Agents Targeting Dipeptidyl Peptidases-IV, -II, 8/9 and Fibroblast Activation Protein
Current Topics in Medicinal Chemistry Imaging Features of Primary Tumors of the Hand
Current Medical Imaging microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The Renaissance of the 68Ge/68Ga Radionuclide Generator Initiates New Developments in 68Ga Radiopharmaceutical Chemistry
Current Topics in Medicinal Chemistry Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer
Reviews on Recent Clinical Trials